OTCMKTS:NEVPF Abliva AB (publ) (NEVPF) Stock Price, News & Analysis $0.03 0.00 (0.00%) As of 09/25/2026 Add Compare Share Share Stock Analysis Stock AnalysisChart About Abliva AB (publ) Stock (OTCMKTS:NEVPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Abliva AB (publ) alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.0352-Week Range$0.01▼$0.04VolumeN/AAverage Volume4,445 shsMarket Capitalization$11.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Abliva AB (publ) is a Swedish biopharmaceutical company focused on developing treatments for primary mitochondrial diseases, a group of rare disorders caused by impaired mitochondrial function. The company’s research is aimed at addressing serious conditions for which treatment options remain limited. Abliva’s lead investigational product is KL1333, an orally administered small-molecule therapy designed to improve cellular energy metabolism in adults with primary mitochondrial disease. The company has also advanced NV354, an experimental compound being developed for mitochondrial complex I deficiency and related energy-production disorders. These candidates remain investigational and have not been established as approved treatments. The company is headquartered in Lund, Sweden, and has historically focused its activities on international drug development through clinical research and collaborations. Abliva was formerly known as NeuroVive Pharmaceutical AB before adopting its current name in 2020. Its programs have been developed for patients with rare mitochondrial diseases in markets including Europe and North America.AI Generated. May Contain Errors. Read More Receive NEVPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abliva AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NEVPF Stock News HeadlinesPharming announces public cash offer to shareholders of Abliva ABDecember 16, 2024 | markets.businessinsider.comStillfront Group publ AB (SFRG)July 27, 2024 | investing.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.September 28 at 1:00 AM | Stansberry Research (Ad)Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial DiseaseJuly 19, 2024 | markets.businessinsider.comAbliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024May 13, 2024 | finance.yahoo.comIVSXF Investor AB (publ)January 9, 2024 | seekingalpha.comInterfox Resources publ AB (IFOX)October 2, 2023 | investing.comCell Impact publ AB (CELLI)October 14, 2022 | investing.comSee More Headlines NEVPF Stock Analysis - Frequently Asked Questions How have NEVPF shares performed this year? Abliva AB (publ)'s stock was trading at $0.0280 at the start of the year. Since then, NEVPF shares have increased by 0.0% and is now trading at $0.0280. How do I buy shares of Abliva AB (publ)? Shares of NEVPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/28/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:NEVPF CIKN/A Webwww.neurovive.com Phone(646) 275-6220Fax46-4-688-883-48Employees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.01 million Net MarginsN/A Pretax MarginN/A Return on Equity-117.92% Return on Assets-102.44% Debt Debt-to-Equity RatioN/A Current Ratio7.99 Quick Ratio7.99 Sales & Book Value Annual Sales$10 thousand Price / Sales1,128.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book1.40Miscellaneous Outstanding Shares403,010,000Free FloatN/AMarket Cap$11.28 million OptionableNot Optionable Beta-1.18 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:NEVPF) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abliva AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Abliva AB (publ) With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
